Liver dysfunction in pathogenesis of burn disease and its correction with succinate-containing drugs

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Current information on the effects of extensive and deep burns upon the liver functions as well as some novel methods of its correction with succinic acid derivates are reviewed. The liver is the main target organ for extensive burn injuries. Manifestations of cytolytic and cholestatic syndrome were observed already on the first days of the disease. To correct these conditions a comprehensive layout of the infusion of intensive therapy is needed. In burn disease it is impossible to restore the circulating blood volume only by infusion of plasma-substituting solutions. Thus, these cocktails must contain drugs, stabilizing metabolic disorders and reducing the concentration of proinflammatory cytokines. Complex intensive therapy in case of burns should also include correction of energy production within the cells without increasing oxygen transport. Substrate antihypoxic drugs are used in order to reduce the need of tissues for oxygen, stabilization of cell membranes and reduction of lipid peroxidation. Succinic acid is a substrate antihypoxic drug capable of detoxification, antihypoxic, antioxidant and hepatoprotective effects. Its derivates modify cellular respiration, compensate for metabolic acidosis, reducing lactate, pyruvate and citrate concentration, normalize histamine and serotonin concentration, improve microcirculation without affecting systemic hemodynamics. All of these effects are pathogenetically substantiated in the treatment of patients with burns. Data regarding the use of drugs on the basis of succinic acid in the treatment of patients with extensive deep burns, critical and supercritical burns during various periods of burn disease, their influence on the severity of multiple organ dysfunction in these patients, the presence of hepatoprotective effect are reported in a few of publications and their conclusions are so far ambiguous enough.

Full Text

Restricted Access

About the authors

Tatiana V Brus

St Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: bant.90@mail.ru
Postgraduate Student, Department of Pathologic Physiology Courses Immunopathology and Medical Informatics Russian Federation

Nikolay V Khaytsev

St Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

Email: nvh195725@gmail.com
MD, PhD in Biological sciences, Professor, Department of Pathologic Physiology Courses Immunopathology and Medical Informatics Russian Federation

Aleftina A Kravtsova

St Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

Email: aleftinakravcova@mail.ru
PhD, Associate Professor, Department of Pathologic Physiology Courses Immunopathology and Medical Informatics Russian Federation

References

  1. Афанасьев В.В., Лукьянова И.Ю. Особенности применения цитофлавина в современной клинической практике. – СПб.: Тактик-Студио, 2010. [Afanas’ev VV, Luk’yanova IYu. Osobennosti primeneniya tsitoflavina v sovremennoy klinicheskoy praktike. Saint Peters¬burg: Taktik-Studio; 2010. (In Russ.)]
  2. Безбородова О.А., Немцова Е.Р., Александрова Л.Н., и др. Оценка детоксицирующего действия препарата «Ремаксол» на модели токсикоза, индуцированного циспластином // Экспериментальная и клиническая фармакология. — 2011. – Т. 74. — № 3. – С. 26–31. [Bezborodova OA, Nemtsova ER, Aleksandrova LN, et al. Otsenka detoksitsiruyushchego deystviya preparata “Remaksol” na modeli toksikoza, indutsirovannogo tsisplastinom. Eksperimental’naya i klinicheskaya farmakologiya. 2011;74(3):26-31. (In Russ.)]
  3. Васильев А.Г., Комяков Б.К., Тагиров Н.С., Мусаев С.А. Чрескожная нефролитотрипсия в лечении коралловидного нефролитиаза // Профилактическая и клиническая медицина. — 2009. — № 4. – С. 183–186. [Vasil’ev AG, Komyakov BK, Tagirov NS, Musaev SA. Chreskozhnaya nefrolitotripsiya v lechenii korallo¬vidnogo nefrolitiaza. Profilakticheskaya i klinicheskaya meditsina. 2009;(4):183-186. (In Russ.)]
  4. Воробьева В.В., Зарубина И.В., Шабанов П.Д., Прошин С.Н. Защитные эффекты антигипоксантов метапрота и этомерзола в модели интоксикации этиленгликолем // Педиатр. — 2015. – Т. 6. — № 6. – С. 59–65. [Vorob’yeva VV, Zarubina IV, Shabanov PD, Proshin SN. Protective effects of antihypoxic substances of metaprot and etomerzol in model ethylene glycol intoxication. Pediatr. 2015;6(6):59-65. (In Russ.)]
  5. Заричавский М.Ф., Каменский Е.Д., Мурагатов И.Н. Оценка эффективности применения ремаксола у больных циррозом печени // Хирургия. — 2013. — № 3. – C. 79–82. [Zarichavskiy MF, Kamenskiy ED, Muragatov IN. Otsenka effektivnosti primeneniya remaksola u bol’nykh tsirrozom pecheni. Khirurgiya. 2013;(3):79-82. (In Russ.)]
  6. Зиновьев Е.В., Нестеров Ю.В., Лагвилава Т.О. Экспериментальная оценка влияния реамберина и цитофлавина на течение и исходы ожоговой болезни // Экспериментальная и клиническая фармакология. — 2013. – Т. 76. — № 4. – C. 39–44. [Zinov’ev EV, Neste¬rov YuV., Lagvilava TO. Eksperimental’naya otsenka vliyaniya reamberina i tsi-toflavina na techenie i iskhody ozhogovoy bolezni. Eksperimental’naya i klinicheskaya farmakologiya. 2013;76(4):39-44. (In Russ.)]
  7. Коваленко А.Л., Власов Т.Д., Чефу С.Г., Смирнова Н.Г. Влияние инфузионного гепатопротектора ремаксол на функцию печени крыс на модели обтурационной желтухи // Экспериментальная и клиническая фармакология. — 2010. — № 9. – С. 24–27. [Kovalenko AL, Vlasov TD, Chefu SG, Smirnova NG. Vliyanie infuzionnogo gepatoprotektora remaksol na funktsiyu pecheni krys na modeli obturatsionnoy zheltukhi. Eksperimental’naya i klinicheskaya farmakologiya. 2010;(9):24-27. (In Russ.)]
  8. Козинец Г.П., Осадчая О.И., Цыганков В.П., и др. Коррекция метаболической гипоксии у пострадавших с тяжелой термической травмой в стадии ожоговой септикотоксемии // Клиническая хирургия. — 2012. — № 12. – С. 38–42. [Kozinets GP, Osadchaya OI, Tsygankov VP, et al. Korrektsiya metabolicheskoy gipoksii u postradavshikh s tyazheloy termicheskoy travmoy v stadii ozhogovoy septikotoksemii. Klinicheskaya khirurgiya. 2012;(12):38-42. (In Russ.)]
  9. Сарвилина И.В. Разработка индивидуальных режимов дозирования реамберина // Вест. Санкт-Петербургской гос. мед. акад. им. И. И. Мечникова. — 2006. — № 1. — С. 94-101. [Sarvilina IV. Razrabotka individual’nykh rezhimov dozirovaniya reamberina. Vest. Sankt-Peterburgskoy gos. med. akad. im. I.I. Mechnikova. 2006;1:94-101. (In Russ.)]
  10. Сологуб Т.В., Горячева Л.Г., Суханов Д.С., и др. Гепатопротективная активность Ремаксола при хронических поражениях печени (материалы многоцентрового рандомизированного плацебо-контролируемого исследования) // Клин. мед. — 2010. — № 1. – С. 62–66. [Sologub TV, Goryacheva LG, Sukhanov DS, et al. Gepatoprotektivnaya aktivnost’ Remaksola pri khronicheskikh porazheniyakh pecheni (materialy mnogotsentrovogo randomizirovannogo platsebo-kontroliruemogo issledovaniya). Klin med. 2010;(1):62-66. (In Russ.)]
  11. Суханов Д.С., Иванов А.К., Романцов М.Г., Коваленко А.Л. Лечение гепатотоксических осложнений противотуберкулезной терапии сукцинатсодержащими препаратами // Рос. мед. журн. — 2009. — № 6. – С. 22–25. [Sukhanov DS, Ivanov AK, Romantsov MG, Kovalenko AL. Lechenie gepatotoksicheskikh oslozhneniy protivotuberkuleznoy terapii suktsinat¬soderzhashchimi preparatami. Ros med zhurn. 2009;(6):22-25. (In Russ.)]
  12. Тагиров Н.С., Назаров Т.Х., Васильев А.Г., и др. Опыт применения чрескожной нефролитотрипсии и контактной уретеролитотрипсии в комплексном лечении мочекаменной болезни // Профилактическая и клиническая медицина. — 2012. — № 4. – С. 30–33. [Tagirov NS, Nazarov TKh, Vasil’ev AG, et al. Opyt primeneniya chreskozhnoy nefrolitotripsii i kontaktnoy ureterolitotripsii v kompleksnom lechenii mochekamennoy bolezni. Profilakticheskaya i klinicheskaya meditsina. 2012;(4):30-33. (In Russ.)]
  13. Цыган Н.В., Трашков А.П., Васильев А.Г., и др. Нейропротекция усиливает нейротрофические механизмы, предотвращая повреждение нейронов и нейроглии при гипоксии мозга // Российские биомедицинские исследования. — 2016. – Т. 1. — № 1. – С. 30–39. [Tsygan NV, Trashkov AP, Vasiliev AG, et al. Neuroprotection boosts neurotrophic mechanisms preventi ng damage of neurons and neuroglia in case of cerebral hypoxia. Russian Biomedical Research. 2016;1(1):30-39. (In Russ.)]
  14. Чурилов Л.П., Васильев А.Г. Патофизиология иммунной системы: Учебное пособие. – СПб.: ФОЛИАНТ, 2014. — 664 c. [Churilov LP, Vasil’ev AG. Patofiziologiya immunnoy sistemy: Uchebnoe posobie. Saint Petersburg: FOLIANT; 2014. 664 p. (In Russ.)]
  15. Anisimov VN, Popovich IG, Zabezhinski MA, et al. Sex differences in aging, life span and spontaneous tumorigenesis in 129/sv mice neonatally exposed to metformin. Cell Cycle. 2015;14(1):46-55. doi: 10.4161/15384101.2014.973308.
  16. Banta S, Vemula M, Yokoyama T, et al. Contribution of gene expression to metabolic fluxes in hypermetabolic livers induced through burn injury and cecal ligation and puncture in rats. Biotechnol. Bioeng. 2007;97:118-137. doi: 10.1002/bit.21200.
  17. Banta S, Yokoyama T, Berthiaume F, Yarmush ML. Effects of dehydroepiandrosterone administration on rat hepatic metabolism following thermal injury. J Surg Res. 2005;127:93-105. doi: 10.1016/j.jss.2005.01.001.
  18. Barrow RE, Hawkins HK, Aarsland A, et al. Identification of factors contributing to hepatomegaly in severely burned children. Shock. 2005;24:523-528. doi: 10.1097/01.shk.0000187981.78901.ee.
  19. Barrow RE, Mlcak R, Barrow LN, Hawkins HK. Increased liver weights in severely burned children: comparison of ultrasound and autopsy measurements. Burns. 2004;30:565-568. doi: 10.1016/j.burns.2004.01.027.
  20. Billich A, Bornancin F, Mechtcheriakova D, et al. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators. Cell Signal. 2005;17:1203-1217. doi: 10.1016/j.cellsig.2004.12.005.
  21. Boyen GB, Steinkamp M, Geerling I, et al. Proinflammatory cytokines induce neurotrophic factor expression in enteric glia: a key to the regulation of epithelial apoptosis in Crohn’s disease. Inflamm Bowel Dis. 2006;12:346-354. doi: 10.1097/01.MIB.0000219350.72483.44.
  22. Bolder U, Jeschke MG, Landmann L, et al. Heat stress enhances recovery of hepatocyte bile acid and organic anion transporters in endotoxemic rats by multiple mechanisms. Cell Stress Chaperones. 2006;11:89-100. doi: 10.1379/CSC-143R.1.
  23. Chen CL, Fei Z, Carter EA, et al. Metabolic fate of extrahepatic arginine in liver after burn injury. Metabolism. 2003;52:1232-1239. doi: 10.1016/S0026-0495(03)00282-8.
  24. Cumming J, Purdue GF, Hunt JL, O’Keefe GE. Objective estimates of the incidence and consequences of multiple organ dysfunction and sepsis after burn trauma. J Trauma. 2001;50:510-5. doi: 10.1097/00005373-200103000-00016.
  25. Dickerson RN, Gervasio JM, Riley ML. Accuracy of predictive methods to estimate resting energy expenditure of thermally-injured patients. JPEN J Parenter Enteral Nutr. 2002;26:17-29. doi: 10.1177/014860710202600117.
  26. Finnerty CC, Herndon DN, Przkora R. Cytokine expression profile over time in severely burned pediatric patients. Shock. 2006;26:13-19. doi: 10.1097/01.shk.0000223120.26394.7d.
  27. Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet. 2004;363:
  28. -1902. doi: 10.1016/S0140-6736(04)16360-5.
  29. Izamis M-L, Sharma N, Uygun B, et al. In situ metabolic flux analysis to quantify the liver metabolic response to experimental burn injury. Biotechnology and Bioengineering. 2011;108(4):839-852. doi: 10.1002/bit.22998.
  30. Jeschke MG. The hepatic response to thermal injury: is the liver important for postburn outcomes. Mol Med. 2009;15:337-351. doi: 10.2119/molmed.2009.00005.
  31. Jeschke MG, Aili Low JF, Spies M, et al. Gastrointestinal and liver physiology. American Journal of Physiology. 2001:280.
  32. Jeschke MG, Barrow RE, Herndon DN. Extended hypermetabolic response of the liver in severely burned pediatric patients. Arch Surg. 2004;139:641-647. doi: 10.1001/archsurg.139.6.641.
  33. Jeschke MG, Bolder U, Chung DH, et al. Gut mucosal homeostasis and cellular mediators after severe thermal trauma, the effect of insulin-like growth factor-I in combination with insulin-like growth factor binding protein-3. Endocrinology. 2006.
  34. Jeschke MG, Gauglitz GG, Song J. Calcium and ER stress mediate hepatic apoptosis after burn injury. J Cell Mol Med. 2009;13:1857-1865. doi: 10.1111/j.1582-4934.2008.00644.x.
  35. Jeschke MG, Chinkes DL, Finnerty CC. Pathophysiologic response to severe burn injury. Ann Surg. 2008;248:387-401. doi: 10.1097/sla.0b013e3181856241.
  36. Jeschke MG, Einspanier R, Klein D, Jauch KW. Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med. 2002;8:443-450.
  37. Jeschke MG, Finnerty CC, Herndon DN. Severe injury is associated with insulin resistance, endoplasmic reticulum stress response, and unfolded protein response. Ann Surg. 2012;255:370-378. doi: 10.1097/SLA.0b013e31823e76e7.
  38. Jeschke MG, Klein D, Herndon DN. Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg. 2004;239:553-560. doi: 10.1097/01.sla.0000118569.10289.ad.
  39. Jeschke MG, Micak RP, Finnerty CC, Herndon DN. Changes in liver function and size after a severe thermal injury. Clinical Aspects. 2007;28(2):172-177. doi: 10.1097/shk.0b013e318047b9e2.
  40. Jeschke MG, Rensing H, Klein D, et al. Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J Hepatol. 2005;42:870-879. doi: 10.1016/j.jhep.2004.12.036.
  41. Klein D, Einspanier R, Bolder U, Jeschke MG. Differences in the hepatic signal transcription pathway and cytokine expression between thermal injury and sepsis. Shock. 2003;20:536-543. doi: 10.1097/01.shk.0000093345.68755.98.
  42. Kraft R, Herndon DN, Finnerty CC, Shahrokhi S. Occurrence of multiorgan dysfunction in pediatric burn patients — incidence and clinical. Ann Surg. 2014;259(2):381-387. doi: 10.1097/SLA.0b013e31828c4d04.
  43. Lee K, Berthiaume F, Stephanopoulos GN, Yarmush ML. Profiling of dynamic changes in hypermetabolic livers. Biotechnol Bioeng. 2003;83:400-415. doi: 10.1002/bit.10682.
  44. Lee K, Berthiaume F, Stephanopoulos GN, et al. Metabolic flux analysis of post-burn hepatic hypermetabolism. Metabol Eng. 2000;2:312-327. doi: 10.1006/mben.2000.0160.
  45. Nugent N, McCormick PA, Orr DJA. Severe acute hepatitis in a burns patient. Burns. 2004;30(6):610-611. doi: 10.1016/j.burns.2004.03.003.
  46. Orman MA, Ierapetritou MG, Androulakis IP, Berthiaume F. Effect of fasting on the metabolic response of liver to experimental burn injury. PLoS ONE. 2013;8(2):1-15. doi: 10.1371/journal.pone.0054825.
  47. Pereira C, Murphy K, Jeschke M. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol. 2005;37:1948-1961. doi: 10.1016/j.biocel.2005.05.009.
  48. Price LA, Thombs B, Chen CL, Milner SM. Liver disease in burn injury: evidence from a national sample of 31,338 adult patients. J Burns Wounds. 2007;7:e1.
  49. Przkora R, Barrow RE, Jeschke MG. Body composition changes with time in pediatric burn patients. J Trauma. 2006;60:968-971. doi: 10.1097/01.ta.0000214580.27501.19.
  50. Steinvall I, Fredrikson M, Bak Z, Sjoberg F. Incidence of early burn-induced effects on liver function as reflected by the plasma disappearance rate of indocyanine green: A prospective descriptive cohort study. Burns. 2012;38:214-224. doi: 10.1016/j.burns.2011.08.017.
  51. Vemula M, Berthiaume F, Jayaraman A, Yarmush ML. Expression profiling analysis of the metabolic and inflammatory changes following burn injury in rats. Physiol Genomics. 2004;18:87-98. doi: 10.1152/physiolgenomics.00189.2003.
  52. Wilmore DW. The effect of glutamine supplementation in patients following elective surgery and accidental injury. J Nutr. 2001;131:2541-2550.
  53. Yu YM, Ryan CM, Castillo L, et al. Arginine and ornithine kinetics in severely burned patients: increased rate of arginine disposal. Am J Physiol Endocrinol Metab. 2001;280:509-517.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Brus T.V., Khaytsev N.V., Kravtsova A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 69634 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies